PROVIDENCE-STRATEGIC
11.9.2020 10:01:09 CEST | Business Wire | Press release
Imaweb/ IDF Group, a leading independent provider of customer relationship management (“CRM”) solutions and dealership management systems (“DMS”) for the automotive industry in Europe, today announced that it has completed its acquisition of TMS-Soft, a leading provider of digital car registration workflow software in France. Imaweb/ IDF Group is backed by Providence Strategic Growth (“PSG”), the growth equity affiliate of premier asset management firm Providence Equity Partners (“Providence”). Financial terms were not disclosed.
Founded in 2008, TMS-Soft automates and streamlines processes associated with vehicle registration through its cutting-edge, digital platform. The company is the largest of only three non-governmental organizations authorized to issue vehicle registration credentials under the French system, the système d'immatriculation des véhicules (SIV). TMS-Soft’s team serves over 3,700 clients ranging from used car dealerships, auto centers, and online car sales marketplaces.
Patrick Prajs, CEO of Imaweb/ IDF Group, said, “Our acquisition of TMS-Soft will enable us to offer clients a highly valuable add-on to their existing suite of Imaweb/IDF Group products, which are centered around our core CRM and DMS products. We will also be able to reach a broader base of customers – especially used-car dealerships – across all our markets. Today’s announcement is a testament of the momentum we have sustained since partnering with PSG, and we are optimistic about the road ahead. We are pleased to welcome the TMS-Soft team to our family and look forward to working together as we solidify our position as a leading European provider of CRM, DMS, and now digital workflow solutions for the automotive industry in Europe.”
Lionel Amrouche, Founder and CEO of TMS-Soft, said, “This transaction underscores the strength of the TMS-Soft brand and importance of our offering. We are excited for the future and look forward to growing the business under the Imaweb/ IDF Group umbrella.”
Since its formation following PSG’s investment in September 2019, Imaweb/ IDF Group has become one of Europe’s premier full-service providers of automotive CRM, DMS and other digital solutions. In the last 12 months, Imaweb/ IDF Group has also completed the acquisitions of ITMotive, a Netherlands-based distributor and servicer of DMS in the Benelux region, and Serinfer, the computer software segment of the Alvariño Group, a Spanish developer, distributor and supplier of DMS.
Imaweb/ IDF Group
Imaweb/ Datafirst-I’Car Systems Group (“Imaweb/ IDF Group”) is a leading developer of CRM and DMS solutions for the automotive sector in Europe. The company was formed through the merger of Imaweb, a Spanish company dedicated to developing global customer management solutions for sales, marketing and after-sales, and DATAFIRST-I’Car Systems, a French software development company for car manufacturers, groups distribution and dealers, in 2019.
TMS-Soft
TMS-Soft is one of only three non-governmental organizations authorized to issue vehicle registration credentials under the French system, the système d'immatriculation des véhicules (SIV). Through its digital platform, TMS-Soft facilitates all formalities associated with the registration process, with a focus on used vehicle registration. TMS-Soft was founded in 2008 by Lionel Amrouche, who continues to lead the business, and is powered by a team serving over 3,700 clients. Please visit https://www.tms-soft.fr/ for more information.
Providence Strategic Growth
PSG is an affiliate of Providence Equity Partners (“Providence”). Established in 2014, PSG focuses on growth equity investments in lower middle market software and technology-enabled service companies. Providence is a premier global asset management firm that pioneered a sector-focused approach to private equity investing with the vision that a dedicated team of industry experts could build exceptional companies of enduring value. Since the firm’s inception in 1989, Providence has invested in more than 200 companies and is a leading equity investment firm focused on the media, communications, education, software and services industries. PSG is headquartered in Boston, MA, with offices in London and Kansas City. For more information on PSG, please visit https://www.provequity.com/private-equity/psg , and for more information on Providence, please visit https://www.provequity.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20200911005129/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
NTT DOCOMO BUSINESS and Chile’s State-owned Copper Company CODELCO Launch a Study and Proof of Concept Aimed at Improving the Efficiency of Remote Copper Mine Operations Using IOWN® APN6.8.2026 06:30:00 CEST | Press release
NTT DOCOMO BUSINESS, Inc. (formerly NTT Communications Corporation) has launched a study and proof of concept jointly with Corporación Nacional del Cobre de Chile (CODELCO) to progress remote operations at CODELCO’s copper mines using an IOWN® All-Photonics Network (APN).1 This initiative is part of a research project commissioned by Japan’s Ministry of Internal Affairs and Communications.2 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260806845222/en/ Conceptual Diagram of the Demonstration To address operational challenges faced by CODELCO’s copper mines, the initiative will connect a copper mine and a remote operations center—approximately 1,500 km apart—via an IOWN APN. It will assess the feasibility of remotely operating heavy machinery using high-capacity, low-latency communication links, enhancing monitoring operations through high-definition video, and implementing a remote operations model. 1. Background Chile is o
FPT Named an OpenAI Select Partner6.8.2026 02:00:00 CEST | Press release
Global IT corporation FPT today announced that it has been named an OpenAI Select Partner within the OpenAI Partner Network. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260805503787/en/ FPT Named an OpenAI Select Partner The OpenAI Partner Network is a global program for partners to build, sell, and deliver AI solutions with OpenAI. It brings together partners with deep industry expertise, delivery capabilities, and customer relationships while equipping them with resources, enablement, and support to help enterprises adopt OpenAI frontier models and products and turn them into measurable impact. As an OpenAI Select Partner, FPT will continue working with OpenAI to help organizations build, deploy, and scale AI solutions responsibly and effectively. This work will help organizations get more useful work from every token and stronger performance per dollar with GPT‑5.6, while using ChatGPT Work to turn ambitious goals into
U.S. FDA Approves Takeda’s ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 16.8.2026 00:10:00 CEST | Press release
Adults Taking ORZEYFUL Experienced Significant and Meaningful Improvements Across the Full Range of Symptoms of Narcolepsy Type 1 (NT1) in Clinical Trials Compared to Those on Placebo As a First-in-Class Orexin Treatment, ORZEYFUL has the Potential to Redefine NT1 Care Beyond Individual Symptoms Takeda is Advancing U.S. Launch Preparations and Expects to Make ORZEYFUL Available Following Completion of the Drug Enforcement Administration (DEA) Scheduling Process Takeda (TSE:4502/NYSE:TAK) announced that the U.S. Food and Drug Administration (FDA) approved ORZEYFUL™ (oveporexton), an oral orexin receptor 2 (OX2R) agonist, for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults.* The persistent 24-hour nature of NT1 is driven by orexin deficiency and can severely impact people’s lives. As a first-in-class orexin treatment, ORZEYFUL is the only medicine indicated in the U.S. to treat the disease holistically rather than individual symptoms. “The FDA approval of OR
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)5.8.2026 22:30:00 CEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to fourteen newly hired non-executive employees. The equity awards were granted on August 3, 2026 and consisted of options to purchase an aggregate of 139,355 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 66,300 shares. The options have an exercise price per share equal to $11.25, the closing price of the Company’s American Depositary Shares on the Nasdaq Global Select Market on the grant date, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in equal monthly installments over the three-year period thereafter, subject to each employee’s continued employment. The restricted
Clinilabs Announces Medical Leadership Appointments5.8.2026 16:05:00 CEST | Press release
Bob Dagher, M.D., Named Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., Named Principal Investigator Clinilabs (“Clinilabs LLC”), a global, full-service contract research organization (CRO) specializing in central nervous system (CNS) drug and device development, today announced the appointments of Bob Dagher, M.D., as Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., as Principal Investigator of the Company’s Eatontown, New Jersey Clinical Research Unit (CRU). Dr. Dagher will provide strategic and medical leadership across the organization, while Dr. Siddiqui will lead the execution of research projects at the Company’s CRU. Together, they will support the design, development, and execution of clinical programs for pharmaceutical, biotechnology, and medical device sponsors advancing innovative therapies for psychiatric, neurological, substance use, and rare CNS disorders. “Clinilabs has earned the trust of sponsors by combining deep scientific expertise, medical leadership,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom